After reporting non-statistically significant results in a phase-II study, Cambridge, Mass.-based Seres Therapeutics is launching a revised phase-II study for its SER-109 Clostridium Difficile treatment.
A Spherix Global Insights report found Janssen Pharmaceuticals’ Stelara, an alternative mechanism biologic, was the most exciting advancement to happen to inflammatory bowel disease in 2016.
The FDA issued a communication claiming Viberzi — a medicine used for patients with irritable bowel syndrome with diarrhea — could increase pancreatitis risk in patients without gallbladders. Parsippany-Troy Hills, N.J.-based Allergan manufactures the drug. The FDA and Allergan are addressing potential safety concerns.
More articles on gastroenterology:
GI leader to know: Dr. John Inadmoi of University of Washington Medicine
Series Therapeutics initiating new phase-II study for C. Diff treatment: 6 insights
National Cancer Institute’s colorectal cancer screening initiative seeks to increase Kentucky screening rates: 4 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
